CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

Migraine and Headache

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

J Headache Pain.

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A

doi: 10.1186/s10194-018-0840-8.

COMMENTED

Migraine and Headache

Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study

JAMA Neurol.

Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B, Boutron-Ruault MC, Kurth T, Bonnet F

doi: 10.1001/jamaneurol.

RECOMMENDED

Migraine and Headache

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Neurology.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK

doi: 10.1212/WNL.

Migraine and Headache

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Headache.

Lipton RB, Hutchinson S, Ailani J, Reed ML, Fanning KM, Manack Adams A, Buse DC

doi: 10.1111/head.13642.

Migraine and Headache

Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study

Headache.

Alpuente A, Gallardo VJ, Torres-Ferrús M, Álvarez-Sabin J, Pozo-Rosich P

doi: 10.1111/head.13765.

Migraine and Headache

Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Headache.

Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, Lipton RB

doi: 10.1111/head.13435.

Migraine and Headache

Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience

Headache.

Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, Cevoli S, D'Amico D, Grazzi L

doi: 10.1111/head.13617.

Migraine and Headache

Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain

BMJ Open.

Palacios-Ceña D, Neira-Martín B, Silva-Hernández L, Mayo-Canalejo D, Florencio LL, Fernández-de-Las-Peñas C, García-Moreno H, García-Azorín D, Cuadrado ML

doi: 10.1136/

Migraine and Headache

Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine

Headache.

Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y

doi: 10.1111/head.13654.

Related content

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study

Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience

Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain

Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine